seqirus.com
Search    
Include All CSL Sites

News

Media Contacts:

Europe 


Stephanie Birkett
Mobile: +44 7917720143
Email: stephanie.birkett@seqirus.com

United States


David Minella
Mobile: +1 919 802 7641
Email: david.minella@seqirus.com

Asia Pacific


Melanie Kerin
Mobile: +61 (0) 417 436 329
Email: melanie.kerin@seqirus.com

11/16/2018
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
Seqirus, a wholly owned subsidiary of CSL Limited and a global leader in influenza prevention, today announced a $140M expansion of its Holly Springs manufacturing facility in North Carolina. More.

10/19/2018
Seqirus Cell-based Influenza Vaccine Nears European Approval
Seqirus, a global leader in influenza prevention, today announced that its cell-based quadrivalent influenza vaccine (QIVc) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for use in people aged 9 years and above. More.

04/17/2018
New PNG Snakebite Project to Improve Access to Antivenoms
A new partnership to help save the lives of people bitten by venomous snakes was launched today in Port Moresby. The ‘PNG Snakebite Partnership’ is a three-year project involving the National Department of Health, the Australian Government, Seqirus Pty Ltd, and the Charles Campbell Toxinology Centre, at the University of Papua New Guinea (UPNG). More.

12/04/2017
Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors
Seqirus today, in partnership with leading health care provider advocacy organizations, announced the launch of Be FLUent, a collaborative initiative that brings together nurse practitioners, physician assistants and pharmacists to drive dialogue about influenza (flu) prevention between health care providers and their patients age 65 and older. More.

11/16/2017
JCVI advocates adjuvanted influenza vaccine for patients aged 65 years and over for 2018-19 influenza season
The Joint Committee on Vaccination and Immunisation (JCVI) has advised that GPs and other healthcare professionals in England should consider using Seqirus’ adjuvanted seasonal influenza vaccine, FLUADⓇ, for the 2018-19 flu season. This because it is both more effective in preventing influenza, and more cost-effective in the 65 years and over age group, when compared to conventional non-adjuvanted vaccines.1 More.

11/08/2017
Major UK investment to boost influenza vaccine production, jobs and exports
Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus, one of the world’s largest influenza vaccine companies, as a result of major new investment announced today. More.

08/07/2017
Seqirus announces major advances in pandemic preparedness
Seqirus, a global leader in the prevention of influenza, announced today that the accelerated development of cell-based manufacturing technology at its state-of-the-art manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats. More.

07/20/2017
Seqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season. More.

06/21/2017
Seqirus announces next major advancement in cell-based influenza vaccine technology
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at the state-of-the art manufacturing facility in Holly Springs, North Carolina. More.

02/25/2016
Joint media release from Invest Liverpool, the Mayor of Liverpool and Seqirus

Today the world’s no. 2 influenza vaccine provider, Seqirus, announced a £22.1m investment for its UK manufacturing site in Liverpool. More.